Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15678813 | 0.88 | KDM4E (0.79) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL31702781 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL29258994 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL31702772 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL31702787 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL5624732 | 0.79 | MEN1 (0.77) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL11267862 | 0.75 | MAOB (0.62) | KDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL11267867 | 0.75 | MAOB (0.62) | KDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL11252794 | 0.73 | KDM4E (0.58) | KDM4EALDH1A1KMT2AGAA | |
| SCHEMBL12825524 | 0.72 | DNMT3B (0.64) | KDM4EALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445537-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | STC.UNM (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | KDM4E 1696/4885ALDH1A1 2436/4885HSD17B10 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.